https://www.mdanderson.org/newsroom/targeted-therapy-tepotinib-for-non-small-cell-lung-cancer-with-met-exon-14-skipping-mutation-shows-durable-response.h00-159381945.html
Targeted therapy tepotinib for non-small cell lung cancer with MET exon 14 skipping mutation shows...
Patients with advanced non-small cell lung cancer (NSCLC) and the MET exon 14 (METex14) skipping mutation had a 46.5% objective response rate to the targeted...
https://pubmed.ncbi.nlm.nih.gov/32328660/
Phase I trial of the MET inhibitor tepotinib in Japanese patients with solid tumors
These results, including initial signals of antitumor activity, support further development of tepotinib in Japanese patients with cancer.